Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2022 June;113(3) > Minerva Medica 2022 June;113(3):518-25

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Medica 2022 June;113(3):518-25

DOI: 10.23736/S0026-4806.21.07776-4

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Prevention of work-related stress, fatigue, loss of cognitive function, improved attention and recovery of stamina with Robuvit® in professionals with increased oxidative stress

Gianni BELCARO 1, 2 , Maria R. CESARONE 1, 2, Aristide SAGGINO 3, Mark DUGALL 1, 2, Shu HU 1, 2, Claudia SCIPIONE 1, 2, Valeria SCIPIONE 1, 2, Umberto CORNELLI 1, 2, Morio HOSOI 1, 2, Roberto COTELLESE 4, David COX 1, 2, Marcello CORSI 1, 2, Beatrice FERAGALLI 4

1 Irvine3 Labs Institute, Pescara, Italy; 2 OOLEX Research Center, Pescara, Italy; 3 Faculty of Psychology, D’Annunzio University, Chieti-Pescara University, Pescara, Italy; 4 Radiology Institute, Department of Medical and Oral Sciences and Biotechnologies, Chieti-Pescara University, Pescara, Italy



BACKGROUND: The aim of this open, pilot supplement registry study was to evaluate the protective, preventive effects of Robuvit® on professional-related fatigue symptoms and on aspects of cognitive functions, professional attitudes and decision-making in healthy nurses under professional stress and with increased oxidative stress.
METHODS: In total, 40 subjects, aged 30-37, completed the 4-week registry study. A control group of 20 subjects used only the standard management (SM) and one group of 20 subjects took 300 mg Robuvit® in addition. Safety and tolerability of Robuvit® were optimal. The two registry groups were comparable at inclusion.
RESULTS: The overall scores of the real daily life and tasks questionnaire after 4 weeks were significantly higher in the Robuvit® group (P<0.05) as compared to controls. It increased from 4.3±0.4 at baseline to 6.78±0.8 after 4 weeks of Robuvit® intake and from 4.2±0.5 to 5.12±1.0 in the control group. The supplementation significantly improved the subjective perception of fatigue in comparison with controls (P<0.05). A practical professional score evaluation provided an indication of professional attitude and stamina, in difficult, stressful working conditions under continuous pressure. The results showed that after 4-week supplementation, all assessed parameters improved significantly and the difference with controls was statistically significant (P<0.05). Furthermore, oxidative stress as plasma free radicals decreased significantly in the Robuvit® group (P<0.05) but not in the control group.
CONCLUSIONS: Robuvit® supplementation appears to improve most symptoms related to work-induced fatigue, stress and cognitive function and supports stamina. Further evaluations need to be planned according to the concept of this pilot registry in a field that requires more attention.


KEY WORDS: Fatigue; Occupational stress; Physical endurance; Robuvit®; Dietary supplements; Oxidative stress; Professional burnout

top of page